A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma (malignant epithelial tumor
with a glandular organization)of the prostate (a gland in the male reproductive
system found below the bladder and in front of the rectum), but not with
neuroendocrine (specialized neurons that produce hormones, such as neuropeptides or
biogenic amines) differentiation or of small cell histology

- Prior chemotherapy (treatment of disease, usually cancer, by chemical agents) for
prostate cancer with regimen(s) containing docetaxel

- Documented prostate specific antigen (PSA) progression according to Prostate Specific
Antigen Working Group (PSAWG) eligibility criteria with a PSA more than (>) 5
nanogram per milliliter (ng/mL) or objective progression by Response Evaluation
Criteria in Solid Tumors (RESIST) criteria

- Ongoing androgen deprivation with serum testosterone less than (<) 50 nanogram per
deciliter (ng/dL)

- Eastern Cooperative Oncology Group (ECOG) Performance Status of less than equal to
(<=) 2 (Karnofsky Performance Status >= 50 percent)

Exclusion Criteria:

- Active or uncontrolled autoimmune disease (disorder in which a person's immune system
attacks parts of his or her own body) that may require corticosteroid therapy

- Serious or uncontrolled co-existent non-malignant disease, including active and
uncontrolled infection

- Uncontrolled hypertension (high blood pressure)

- Hemoglobin <=9.0 gram per deciliter (g/dL) without growth factor or transfusion
support

- Abnormal liver (large organ that helps in many body functions, including digestion,
metabolism, and storage of substances) function